Effect of vildagliptin as add-on therapy to a low-dose metformin

Table 1 Demographic and baseline characteristics (randomized population)

Demographic variable	Vilda 100 mg qd/metformin 500 mg bid N = 456	Metformin up to 1000 mg bid N = 458	Total N = 914
Gender; female, n (%)	226 (49.6)	252 (55)	478 (52.3)
Age; mean ± SD (years)	56.9 ± 9.76	57.0 ± 10.02	57.0 ± 9.89
Age group (≥ 65 years), n (%)	106 (23.2%)	114 (24.9%)	220 (24.1%)
Race
Caucasian	242 (53.1%)	237 (51.7%)	479 (52.4%)
Asian (non-indian subcontinent)	44 (9.6%)	44 (9.6%)	88 (9.6%)
Hispanic or latino	147 (32.2%)	145 (31.7%)	292 (31.9%)
Black	9 (2.0%)	12 (2.6%)	21 (2.3%)
Asian (indian subcontinent)	3 (0.7%)	5 (1.1%)	8 (0.9%)
Native american	1 (0.2%)	2 (0.4%)	3 (0.3%)
Other	10 (2.2%)	13 (2.8%)	23 (2.5%)
Body weight; mean ± SD (kg)	84.6 ± 17.01	84.4 ± 18.94	84.5 ± 17.99
BMI (kg/m2); mean ± SD	31.1 ± 5.11	31.2 ± 5.47	31.1 ± 5.29
HbA1c (%); mean ± SD	7.4 ± 0.78	7.3 ± 0.79a	7.3 ± 0.79
FPG (mmol/L); mean ± SD	8.7 ± 2.28	8.5 ± 2.25	8.6 ± 2.27
Duration of type 2 diabetes; mean ± SD (years)	4.6 ± 4.91	4.7 ± 4.94	4.7 ± 4.92

Demographic information is collected on the day of the screening measurement (Week-4, Visit 1).

^aHemoglobin A_1c (HbA_1c) measurements at Visit 1 not available for one patient (n = 457). FPG: Fasting plasma glucose; BMI: Body mass index.